Hamburg - Delayed Quote EUR
Heidelberg Pharma AG (HPHA.HM)
As of 8:16 AM GMT+1. Market Open.
Breakdown
TTM
11/30/2023
11/30/2022
11/30/2021
11/30/2020
Total Revenue
8,472.0260
9,858.9120
18,513.9200
1,750.0000
8,487.9380
Cost of Revenue
1,659.6880
3,252.8280
4,679.3400
4,712.1220
5,599.7780
Gross Profit
6,812.3380
6,606.0840
13,834.5800
-2,962.1220
2,888.1600
Operating Expense
29,160.5580
34,703.1920
32,238.4110
22,830.6000
21,451.8070
Operating Income
-22,348.2200
-28,097.1080
-18,403.8310
-25,792.7220
-18,563.6470
Net Non Operating Interest Income Expense
1,306.9480
863.3130
-604.6690
-494.0000
-13.5640
Pretax Income
-19,044.1120
-20,346.4860
-17,786.1580
-26,138.7020
-18,369.0380
Tax Provision
-277.4220
--
1,915.9380
--
--
Net Income Common Stockholders
-18,766.6900
-20,346.4860
-19,702.0970
-26,138.7020
-18,369.0380
Diluted NI Available to Com Stockholders
-18,766.6900
-20,346.4860
-19,702.0970
-26,138.7020
-18,369.0380
Basic EPS
-0.41
-0.44
-0.53
-0.80
-0.61
Diluted EPS
-0.41
-0.44
-0.53
-0.80
-0.61
Basic Average Shares
46,154.7050
46,595.7410
37,235.4760
32,504.0680
29,896.6330
Diluted Average Shares
46,604.9770
46,595.7410
37,235.4760
32,504.0680
29,896.6330
Total Operating Income as Reported
-20,351.0590
-21,209.7990
-17,181.4890
-25,631.0640
-18,284.7200
Rent Expense Supplemental
114.0000
--
--
--
--
Total Expenses
30,820.2460
37,956.0200
36,917.7510
27,542.7220
27,051.5850
Net Income from Continuing & Discontinued Operation
-18,766.6900
-20,346.4860
-19,702.0970
-26,138.7020
-18,369.0380
Normalized Income
-18,797.2384
-20,377.4860
-19,714.8470
-26,138.7020
-18,378.0380
Interest Income
1,543.6030
1,624.9130
235.2140
--
--
Interest Expense
236.6550
761.6000
839.8830
494.0000
13.5640
Net Interest Income
1,306.9480
863.3130
-604.6690
-494.0000
-13.5640
EBIT
-18,807.4570
-19,584.8860
-16,946.2750
-25,644.7020
-18,355.4740
EBITDA
-17,937.6360
-18,705.8860
-16,189.2750
-24,841.8420
-17,621.6020
Reconciled Cost of Revenue
1,659.6880
3,252.8280
4,679.3400
4,712.1220
5,599.7780
Reconciled Depreciation
869.8210
879.0000
757.0000
802.8600
733.8720
Net Income from Continuing Operation Net Minority Interest
-18,766.6900
-20,346.4860
-19,702.0970
-26,138.7020
-18,369.0380
Total Unusual Items Excluding Goodwill
31.0000
31.0000
15.0000
--
9.0000
Total Unusual Items
31.0000
31.0000
15.0000
--
9.0000
Normalized EBITDA
-17,968.6360
-18,736.8860
-16,204.2750
-24,841.8420
-17,630.6020
Tax Rate for Calcs
0.0000
--
0.0002
--
--
Tax Effect of Unusual Items
0.4516
--
2.2500
--
--
11/30/2020 - 6/3/2010
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PRLD Prelude Therapeutics Incorporated
1.2700
0.00%
RAPP Rapport Therapeutics, Inc.
26.90
+2.87%
IMAB I-Mab
1.0710
-0.83%
2269.HK WuXi Biologics (Cayman) Inc.
17.120
-2.39%
RAPT RAPT Therapeutics, Inc.
3.1200
+0.64%
MRSN Mersana Therapeutics, Inc.
2.4900
-2.35%
TNGX Tango Therapeutics, Inc.
2.8799
+1.76%
GLUE Monte Rosa Therapeutics, Inc.
9.70
+1.77%
CCCC C4 Therapeutics, Inc.
6.04
0.00%
INCY Incyte Corporation
83.29
+1.16%